-
1دورية أكاديمية
المؤلفون: Maddalena Giglia, Giacomo Beci, Elena Rosselli Del Turco, Viola Guardigni, Alberto Amedeo, Giulia Cucchetto, Gabriella Verucchi, Marco Cipolli, Leonardo Calza, Pierluigi Viale
المصدر: Monaldi Archives for Chest Disease, Vol 90, Iss 4 (2020)
مصطلحات موضوعية: COVID-19, tocilizumab, cystic fibrosis, Medicine
الوصف: We report the case of a man affected by cystic fibrosis who developed a severe SARS-CoV-2 related pneumonia in March 2020. In addition to lopinavir/ritonavir and hydroxychloroquine, he was treated with two doses of tocilizumab, displaying a significant clinical improvement. This is the first case described in the literature of an adult patient affected by cystic fibrosis who received tocilizumab for COVID-19, with documented total recovery, also assessed by a spirometry.
وصف الملف: electronic resource
-
2دورية أكاديمية
المؤلفون: Mario Luca Morieri, Viola Guardigni, Juana Maria Sanz, Edoardo Dalla Nora, Cecilia Soavi, Giovanni Zuliani, Laura Sighinolfi, Angelina Passaro
المصدر: BMC Infectious Diseases, Vol 18, Iss 1, Pp 1-9 (2018)
مصطلحات موضوعية: Adipokines, HIV infections, Highly active antiretroviral therapy, Lipocalin-2, Adipose tissue, Inflammation, Infectious and parasitic diseases, RC109-216
الوصف: Abstract Background Metabolic and cardiovascular diseases (CVD) represent a major problem in HIV infection. The aim of this study was to evaluate the relationship of HIV infection and antiretroviral therapy (ART) with circulating levels of two adipokines (Lipocalin-2 and Fatty Acid Binding Protein-4, FABP-4), known to be associated with adipose tissue dysfunction and cardiovascular disease in the general population. Methods We enrolled 40 non-obese HIV-infected patients and 10 healthy controls of similar age and Body Mass Index (BMI). Body composition, metabolic syndrome, lipid profile, 10-years CVD risk score, and adipokines levels were compared between groups. ART-regimen status (naïve, non-nucleoside reverse transcriptase inhibitors – NNRTIs – and protease inhibitors – PIs) association with adipokines levels was tested with linear regression models. Results HIV patients showed a worse metabolic profile than controls. Lipocalin-2 levels were higher in HIV-infected subjects (+53%; p = 0.007), with a significant trend (p = 0.003) for higher levels among subjects taking NNRTIs. Association of lipocalin-2 with fat-mass and BMI was modulated by ART regimens, being positive among subjects treated with NNRTIs and negative among those treated with PIs (“ART-regimens-by-BMI” interaction p = 0.0009). FABP-4 levels were correlated with age, fat mass, BMI, lipid profile and CVD risk (all R ≥ 0.32, p
وصف الملف: electronic resource
-
3دورية أكاديمية
المؤلفون: Bianca Granozzi, Viola Guardigni, Lorenzo Badia, Elena Rosselli Del Turco, Alberto Zuppiroli, Beatrice Tazza, Pietro Malosso, Stefano Pieralli, Pierluigi Viale, Gabriella Verucchi
المصدر: Journal of Clinical Medicine, Vol 10, Iss 21, p 4955 (2021)
مصطلحات موضوعية: PWID, homeless persons, HCV eradication, direct-acting antivirals, out-of-hospital, retention in care, Medicine
الوصف: Background. People who inject drugs (PWID) and homeless people represent now a large reservoir of Hepatitis C virus (HCV) infection. However, Hepatis C elimination programs can barely reach these subgroups of patients. We aimed to evaluate and compare the retention in care among these difficult-to-treat patients when managed for HCV in hospital or in an out-of-hospital setting. Methods. In our retrospective study, we categorized the included patients (PWID and homeless persons) into two groups according to whether anti-HCV treatment was offered and provided in a hospital or an out-of-hospital setting. We run logistic regressions to evaluate factors associated with retention in care (defined as the completion of direct antiviral agents (DAAs) therapy). Results. We included 56 patients in our study: 27 were in the out-of-hospital group. Overall, 33 patients completed DAAs therapy. A higher rate of retention in care was observed in the out-of-hospital group rather than in-hospital group (p = 0.001). At the univariate analysis, retention in care was associated with the out-of-hospital management (p = 0.002) and with a shorter time between the first visit and the scheduled start of DAAs (p = 0.003). Conclusions. The choice of treatment models that can better adapt to difficult-to-treat populations, such as an out-of-hospital approach, will be important for achieving the eradication of HCV infection.
وصف الملف: electronic resource
-
4دورية أكاديمية
المؤلفون: Renato Pascale, Viola Guardigni, Lorenzo Badia, Francesca Volpato, Pierluigi Viale, Gabriella Verucchi
المصدر: Case Reports in Hepatology, Vol 2017 (2017)
مصطلحات موضوعية: Diseases of the digestive system. Gastroenterology, RC799-869
الوصف: Tenofovir disoproxil fumarate- (TDF-) related nephropathy is known to be a long-term complication of this drug, more commonly observed in HIV-infected patients, but occurring also in hepatitis B. Cases of Fanconi Syndrome associated with TDF have been reported in adult patients, usually as a long-term complication of chronic hepatitis B treatment. We present here a case of a 12-year-old male developing a severe acute HBV hepatitis treated with TDF. The patient achieved an early virological and biochemical response, but with a subsequent onset of proximal renal tubular damage, consistent with Fanconi Syndrome. After withdrawing this drug and switching to Entecavir, a complete resolution of tubulopathy and, after 6 months, a complete HBsAg seroconversion occurred. To our knowledge, this is the first report of an early renal injury due to TDF-therapy in a pediatric patient treated for acute hepatitis B.
وصف الملف: electronic resource
-
5دورية أكاديمية
المؤلفون: Viola Guardigni, Gabriele Fabbri, Anastasio Grilli, Carlo Contini
المصدر: Annals of Hepatology, Vol 11, Iss 3, Pp 404-408 (2012)
مصطلحات موضوعية: Charcot Marie Tooth Disease, Ehlers-Danlos Syndrome, Peg-Interferon, HCV, Specialties of internal medicine, RC581-951
الوصف: Antiviral therapy in patients suffering from chronic hepatitis C virus (HCV) infection and rare comorbidities cannot be easily started, as it can reduce the likelihood of a good therapeutic response with an increased frequency of side effects. We report two patients presenting unusual comorbidities associated with chronic C hepatitis: one with the Ehlers-Danlos Syndrome (EDS), a rare genetic disease caused by a defect in collagen synthesis, the other one with the Charcot Marie Tooth (CMT) disease, an uncommon but severe form of demyelinating peripheral neuropathy. Both patients were successfully treated with pegylated Interfe-ron (Peg-IFN) and ribavirin (RBV) combined therapy, with the achievement of a sustained viral response (SVR) and a low occurrence of adverse effects. Up to now there are no reports of patients suffering from chronic C hepatitis associated with these uncommon but severe comorbidities treated with antiviral therapy. In conclusion, in such clinical situations, anti-HCV therapy may be started and tailored, especially if the patient is highly motivated and if optimal predictors of response (i.e. young age, favourable genotype and low baseline viraemia) do exist.
وصف الملف: electronic resource
Relation: http://www.sciencedirect.com/science/article/pii/S1665268119309391; https://doaj.org/toc/1665-2681
-
6
المؤلفون: Alice Toschi, Eleonora Salsi, Gabriella Verucchi, Gabriele Fabbri, Laura Sighinolfi, Francesco Cristini, Viola Guardigni, Gianluca Cuomo, Lorenzo Badia, Pierluigi Viale, Marco Massari, Elena Rosselli Del Turco
المساهمون: Guardigni V., Toschi A., Badia L., Rosselli Del Turco E., Salsi E., Cristini F., Sighinolfi L., Fabbri G., Massari M., Cuomo G., Viale P., Verucchi G.
المصدر: AIDS. 35:1967-1972
مصطلحات موضوعية: Liver Cirrhosis, medicine.medical_specialty, Carcinoma, Hepatocellular, Cirrhosis, Sustained Virologic Response, Liver Cirrhosi, Hepatitis C virus, antiretroviral therapy, Immunology, Population, Human immunodeficiency virus (HIV), HIV Infections, Hepacivirus, medicine.disease_cause, Antiviral Agents, Gastroenterology, Retrospective Studie, Internal medicine, Genotype, medicine, Humans, hepatitis C viru, Immunology and Allergy, HIV Infection, education, neoplasms, Retrospective Studies, Antiviral Agent, direct-acting antiviral, education.field_of_study, Hepaciviru, business.industry, Liver Neoplasms, HIV, Cancer, hepatocellular carcinoma, Hepatitis C, Chronic, medicine.disease, Hepatitis C, digestive system diseases, Infectious Diseases, Hepatocellular carcinoma, business, Liver cancer, cirrhosi, Human
الوصف: OBJECTIVES: Hepatocellular carcinoma (HCC) has become a major issue in coinfected HIV/HCV patients with liver cirrhosis. We aimed to determine the rate of HCC occurrence after a direct-acting antiviral (DAA) treatment and to evaluate the factors associated with the risk of HCC in this population. DESIGN: We conducted a retrospective multicenter observational study including cirrhotic HIV/HCV-coinfected patients treated with DAAs, between October 2014 and January 2017. METHODS: We collected demographics characteristics, data regarding HIV and HCV infections and treatment with DAAs. We investigated the rate and the time of occurrence of HCC. Statistical analysis explored the factors associated to development of liver cancer. RESULTS: During a median follow-up of 55 months, 24 out of 232 patients developed HCC, after a median of 22.5 months from starting DAAs. Factors associated with HCC were a higher Child--Pugh Turcotte (CPT) score (P = 0.002), HCV genotype 3 (P = 0.04), previous HCC (P
وصف الملف: STAMPA
URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0d1660faf866dbaf9959269ae34aeefd
https://doi.org/10.1097/qad.0000000000002973 -
7
المؤلفون: Silvia Galli, Kristian Scolz, Viola Guardigni, Pierluigi Viale, Gabriella Verucchi, Elena Rosselli Del Turco, Lorenzo Badia
المصدر: Hepatitis Monthly. 21
مصطلحات موضوعية: medicine.medical_specialty, HBsAg, Liver infection, Hepatology, business.industry, Mortality rate, virus diseases, Retrospective cohort study, Hepatitis B, medicine.disease, Intensive care unit, digestive system diseases, law.invention, Infectious Diseases, law, Internal medicine, Cohort, medicine, business, Viral hepatitis
الوصف: Background: A better understanding of the interaction between SARS-CoV-2 infection and HBV or HCV hepatitis is very important. Objectives: We aimed to determine the prevalence and the impact of pre-existing HBV and HCV infections in patients with COVID-19. Methods: We conducted a retrospective study and included all the subjects positive for SARS-CoV-2 from March to May 2020. We evaluated the prevalence of chronic HBV and HCV infections and performed a matched cohort analysis to compare COVID-19-related outcomes between patients with and without infections due to HBV or HCV. Results: Among 606 subjects, 12 cases (2%) had positive HBsAg, and 6 cases (0.99%) presented detectable HCV RNA. We recognized 80 individuals positive for SARS-CoV-2 with negative markers for HBV and HCV suitable for the matched analysis. No statistical dif-ferences in mechanical ventilation support and mortality rates were found (P = 0.27 and P = 0.80, respectively). Moreover, although not statistically different, individuals with viral hepatitis were more likely to be admitted to the Intensive Care Unit in comparison to those without HBV or HCV infections (29% vs. 15%). The median time of virus clearance was 27.5 days, with no difference between the two groups. Conclusions: In our cohort, the pre-existing viral liver infection did not have any impact on the clinical and virological evolution of COVID-19. © 2021, Author(s).
URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_________::ba472dd47ce3c34a684484fdff0a894d
https://doi.org/10.5812/hepatmon.116986 -
8
المؤلفون: Silvia Galli, Elena Rosselli Del Turco, Maria Carla Re, Pierluigi Viale, Viola Guardigni, Gabriella Verucchi, Kristian Scolz
مصطلحات موضوعية: business.industry, Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), medicine, Retrospective cohort study, Observational study, Disease, Viral hepatitis, medicine.disease, Bioinformatics, Affect (psychology), business
الوصف: BACKGROUND: To date, data about prevalence and clinical impact of viral hepatitis in COVID-19 are scarce and conflicting.METHODS: We conducted an observational, retrospective study including all subjects tested positive for SARS-CoV-2 from March to May 2020. We evaluated prevalence of chronic viral hepatitis and we performed a matched cohort analysis of patients with and without chronic viral hepatitis comparing COVID-related outcomes.RESULTS: 980 subjects resulted positive to SARS-CoV-2 on oropharyngeal swabs. Among them 12 (1,2%) were HBsAg positive and 6 (0,6%) had detectable HCV RNA. No one was receiving antiviral therapy. None of these had a documented liver cirrhosis.We identified 80 SARS-CoV-2 positive individuals with negative viral markers for HBV and HCV for the matched analysis. No statistical differences in hospitalization, need for MV and mortality rates (p 0.79, p 0.28 and p 0.8, respectively) were found. Although not statistically significant (p 0.12), a higher rate of those positive for viral hepatitis were admitted to ICU (29% Vs 15%). Median time of virus clearance was 27.5 (IQR 20,38) days, with no difference between the two groups (p 0.39, 95% CI (-12;4.8)). We found older age and male sex as factors associated with worse outcomes.CONCLUSION: Our analysis documented similar rates of chronic viral hepatitis among subjects with SARS-CoV-2 infection and general population. Furthermore, in our population, pre-existing viral liver infection did not have any impact on the clinical and virological course of COVID-19.
URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_________::9878d0fbe79692e9108eb66303cab6f7
https://doi.org/10.21203/rs.3.rs-99544/v1 -
9
المؤلفون: Leonardo Calza, Marco Cipolli, Maddalena Giglia, Gabriella Verucchi, Giacomo Beci, Viola Guardigni, Giulia Cucchetto, Pierluigi Viale, Elena Rosselli Del Turco, Alberto Amedeo
المساهمون: Giglia M., Beci G., Del Turco E.R., Guardigni V., Amedeo A., Cucchetto G., Verucchi G., Cipolli M., Calza L., Viale P.
المصدر: Monaldi Archives for Chest Disease, Vol 90, Iss 4 (2020)
مصطلحات موضوعية: Male, Cystic Fibrosis, lcsh:Medicine, Cystic fibrosis, Lopinavir, chemistry.chemical_compound, Drug Combination, Respiratory Tract Infection, skin and connective tissue diseases, Lung, Respiratory Tract Infections, Respiratory Function Test, medicine.diagnostic_test, virus diseases, Tocilizumab, Respiratory Function Tests, Drug Combinations, medicine.anatomical_structure, Treatment Outcome, Cystic fibrosi, Cardiology and Cardiovascular Medicine, medicine.drug, Human, Hydroxychloroquine, Pulmonary and Respiratory Medicine, Spirometry, Adult, medicine.medical_specialty, Pneumonia, Viral, Antibodies, Monoclonal, Humanized, Antiviral Agents, Internal medicine, medicine, Humans, Antiviral Agent, Ritonavir, business.industry, SARS-CoV-2, lcsh:R, Oxygen Inhalation Therapy, COVID-19, medicine.disease, Receptors, Interleukin-6, COVID-19 Drug Treatment, Pneumonia, chemistry, business, Tomography, X-Ray Computed
الوصف: We report the case of a man affected by cystic fibrosis who developed a severe SARS-CoV-2 related pneumonia in March 2020. In addition to lopinavir/ritonavir and hydroxychloroquine, he was treated with two doses of tocilizumab, displaying a significant clinical improvement. This is the first case described in the literature of an adult patient affected by cystic fibrosis who received tocilizumab for COVID-19, with documented total recovery, also assessed by a spirometry. was first described in December 2019 in Wuhan, China, and was declared pandemic by the World Health Organization (WHO) on March 11th, 2020. The clinical spectrum varies widely, from asymptomatic infection or mild influenza-like disease to potentially fatal pneumonia with respiratory failure. Hypertension, diabetes and coronary heart disease have already been described as common comorbidities and are linked, with various degrees of importance, with a worse evolution and outcome of the infection, both in preliminary papers and in most recent evaluations. With respect to respiratory tract pathological conditions, chronic obstructive pulmonary disease (COPD) and active smoking have been reported as factors linked to more severe outcomes [1]. Spread of Covid-19 among patients with cystic fibrosis (CF) might have a severe impact on their clinical conditions. To date, few data are available on the association of these two diseases.
وصف الملف: ELETTRONICO
URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d9d9523e1c4b57b0813410c2c13c27e4
https://pubmed.ncbi.nlm.nih.gov/33372741 -
10
المؤلفون: Ciro Fulgaro, Ioannis Tzimas, Luigi Raumer, Marianna Meschiari, Marianna Menozzi, Gabriella Verucchi, Giada Rossini, Filippo Trapani, Giacomo Fornaro, Michela Semprini, Alessandra Cascavilla, Emanuele Campaci, Maddalena Giannella, Luigia Scudeller, Alessandro Zuccotti, Irid Baxhaku, Lucia Angelelli, Eleonora Zamparini, Annalisa Saracino, Alberto Zuppiroli, Cristina Basso, Elisabetta Pierucci, Agostino Rossi, Giulia Santangelo, Paolo Gaibani, Francesco Cristini, Francesca Volpato, Elisa Fronti, Giovanni Guaraldi, Alberto Sarti, Giorgio Legnani, Mattia Neri, Mauro Codeluppi, Adriana Badeanu, Giulio Virgili, Chiara Pironi, Lorenzo Marconi, Sara K. Tedeschi, Vidak Koprivika, Francesco Barchiesi, Luciano Attard, Matteo Rinaldi, Paola Laghetti, Stefano Antonini, Linda Bussini, Caterina Campoli, Giacomo Urbinati, Marco Merli, Nicholas Roncagli, Agnese Pratelli, Elena Rosselli Del Turco, Silvia Rapuano, Luca Guerra, Stefano Ianniruberto, Francesco Dell'Omo, Michele Bartoletti, Livia Pancaldi, Viola Guardigni, Fabio Tumietto, Giuseppe Sasdelli, Vito Marco Ranieri, Flovia Dauti, Giovanni Fasulo, Eugenia Francalanci, Nicola Dentale, Amalia Sanna Passino, Tommaso Zanaboni, Arianna Rubin, Davide Fiore Bavaro, Idina Zavatta, Massimo Puoti, Letizia Pasinelli, Maria Cristina Leoni, Pierluigi Viale, Oana Vatamanu, Elena Piccini, Renato Pascale, Cristina Mussini, Luca Esposito, Simona Coladonato, Alice Gori, Giulia Tesini, Lorenzo Badia, Mara D'Onofrio, Alberto Licci, Enrico Evangelisti, Guido Maria Liuzzi, Giacinto Pizzilli, Nicolò Rossi, Tommaso Tonetti, Marina Tadolini, Zeno Pasquini, Caterina Vocale
المساهمون: Bartoletti M., Giannella M., Scudeller L., Tedeschi S., Rinaldi M., Bussini L., Fornaro G., Pascale R., Pancaldi L., Pasquini Z., Trapani F., Badia L., Campoli C., Tadolini M., Attard L., Puoti M., Merli M., Mussini C., Menozzi M., Meschiari M., Codeluppi M., Barchiesi F., Cristini F., Saracino A., Licci A., Rapuano S., Tonetti T., Gaibani P., Ranieri V.M., Viale P., Raumer L., Guerra L., Tumietto F., Cascavilla A., Zamparini E., Verucchi G., Coladonato S., Rubin A., Ianniruberto S., Francalanci E., Volpato F., Virgili G., Rossi N., Del Turco E.R., Guardigni V., Fasulo G., Dentale N., Fulgaro C., Legnani G., Campaci E., Basso C., Zuppiroli A., Passino A.S., Tesini G., Angelelli L., Badeanu A., Rossi A., Santangelo G., Dauti F., Koprivika V., Roncagli N., Tzimas I., Liuzzi G.M., Baxhaku I., Pasinelli L., Neri M., Zanaboni T., Dell'Omo F., Vatamanu O., Gori A., Zavatta I., Antonini S., Pironi C., Piccini E., Esposito L., Zuccotti A., Urbinati G., Pratelli A., Sarti A., Semprini M., Evangelisti E., D'Onofrio M., Sasdelli G., Pizzilli G., Pierucci E., Rossini G., Vocale C., Marconi L., Leoni M.C., Fronti E., Guaraldi G., Bavaro D., Laghetti P., Bartoletti, M, Giannella, M, Scudeller, L, Tedeschi, S, Rinaldi, M, Bussini, L, Fornaro, G, Pascale, R, Pancaldi, L, Pasquini, Z, Trapani, F, Badia, L, Campoli, C, Tadolini, M, Attard, L, Puoti, M, Merli, M, Mussini, C, Menozzi, M, Meschiari, M, Codeluppi, M, Barchiesi, F, Cristini, F, Saracino, A, Licci, A, Rapuano, S, Tonetti, T, Gaibani, P, Ranieri, V, Viale, P, Raumer, L, Guerra, L, Tumietto, F, Cascavilla, A, Zamparini, E, Verucchi, G, Coladonato, S, Rubin, A, Ianniruberto, S, Francalanci, E, Volpato, F, Virgili, G, Rossi, N, Del Turco, E, Guardigni, V, Fasulo, G, Dentale, N, Fulgaro, C, Legnani, G, Campaci, E, Basso, C, Zuppiroli, A, Passino, A, Tesini, G, Angelelli, L, Badeanu, A, Rossi, A, Santangelo, G, Dauti, F, Koprivika, V, Roncagli, N, Tzimas, I, Liuzzi, G, Baxhaku, I, Pasinelli, L, Neri, M, Zanaboni, T, Dell'Omo, F, Vatamanu, O, Gori, A, Zavatta, I, Antonini, S, Pironi, C, Piccini, E, Esposito, L, Zuccotti, A, Urbinati, G, Pratelli, A, Sarti, A, Semprini, M, Evangelisti, E, D'Onofrio, M, Sasdelli, G, Pizzilli, G, Pierucci, E, Rossini, G, Vocale, C, Marconi, L, Leoni, M, Fronti, E, Guaraldi, G, Bavaro, D, Laghetti, P
المصدر: Clinical Microbiology and Infection
مصطلحات موضوعية: 0301 basic medicine, Male, Logistic regression, prognostic tool, 0302 clinical medicine, Risk Factors, Positive predicative value, Severe acute respiratory syndrome coronavirus 2, 030212 general & internal medicine, Child, Aged, 80 and over, Framingham Risk Score, Coronavirus disease 2019, Respiratory distress, Lactate dehydrogenase, General Medicine, Middle Aged, Prognosis, Hospitalization, Infectious Diseases, Italy, Child, Preschool, Female, Coronavirus Infections, Respiratory Insufficiency, Cohort study, Microbiology (medical), Adult, medicine.medical_specialty, Respiratory rate, Adolescent, COVID-19, SARS-CoV-2, severe respiratory failure, 030106 microbiology, Pneumonia, Viral, Risk Assessment, Sensitivity and Specificity, Article, 03 medical and health sciences, Betacoronavirus, Young Adult, Age, Internal medicine, medicine, Humans, Obesity, Pandemics, Aged, Retrospective Studies, business.industry, Reproducibility of Results, Retrospective cohort study, Logistic Models, Respiratory failure, Multivariate Analysis, business, C-reactive proteine
الوصف: Objectives: We aimed to develop and validate a risk score to predict severe respiratory failure (SRF) among patients hospitalized with coronavirus disease-2019 (COVID-19). Methods: We performed a multicentre cohort study among hospitalized (>24 hours) patients diagnosed with COVID-19 from 22 February to 3 April 2020, at 11 Italian hospitals. Patients were divided into derivation and validation cohorts according to random sorting of hospitals. SRF was assessed from admission to hospital discharge and was defined as: SpO2 30 breaths/min or respiratory distress. Multivariable logistic regression models were built to identify predictors of SRF, β-coefficients were used to develop a risk score. Trial Registration NCT04316949. Results: We analysed 1113 patients (644 derivation, 469 validation cohort). Mean (±SD) age was 65.7 (±15) years, 704 (63.3%) were male. SRF occurred in 189/644 (29%) and 187/469 (40%) patients in the derivation and validation cohorts, respectively. At multivariate analysis, risk factors for SRF in the derivation cohort assessed at hospitalization were age ≥70 years (OR 2.74; 95% CI 1.66–4.50), obesity (OR 4.62; 95% CI 2.78–7.70), body temperature ≥38°C (OR 1.73; 95% CI 1.30–2.29), respiratory rate ≥22 breaths/min (OR 3.75; 95% CI 2.01–7.01), lymphocytes ≤900 cells/mm3 (OR 2.69; 95% CI 1.60–4.51), creatinine ≥1 mg/dL (OR 2.38; 95% CI 1.59–3.56), C-reactive protein ≥10 mg/dL (OR 5.91; 95% CI 4.88–7.17) and lactate dehydrogenase ≥350 IU/L (OR 2.39; 95% CI 1.11–5.11). Assigning points to each variable, an individual risk score (PREDI-CO score) was obtained. Area under the receiver-operator curve was 0.89 (0.86–0.92). At a score of >3, sensitivity, specificity, and positive and negative predictive values were 71.6% (65%–79%), 89.1% (86%–92%), 74% (67%–80%) and 89% (85%–91%), respectively. PREDI-CO score showed similar prognostic ability in the validation cohort: area under the receiver-operator curve 0.85 (0.81–0.88). At a score of >3, sensitivity, specificity, and positive and negative predictive values were 80% (73%–85%), 76% (70%–81%), 69% (60%–74%) and 85% (80%–89%), respectively. Conclusion: PREDI-CO score can be useful to allocate resources and prioritize treatments during the COVID-19 pandemic.
وصف الملف: ELETTRONICO
URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bec3f286a7926131f5da3c8ae6f67eeb
http://europepmc.org/articles/PMC7414420
Full Text Finder 
Find this article in full text from Springer Verlag.